NASDAQ:ADMA ADMA Biologics (ADMA) Stock Price, News & Analysis $17.40 -0.50 (-2.79%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About ADMA Biologics Stock (NASDAQ:ADMA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get ADMA Biologics alerts:Sign Up Key Stats Today's Range$17.08▼$17.9650-Day Range$15.62▼$22.6252-Week Range$4.07▼$23.64Volume6.94 million shsAverage Volume3.57 million shsMarket Capitalization$4.11 billionP/E Ratio62.14Dividend YieldN/APrice Target$21.25Consensus RatingBuy Company OverviewADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.Read More… ADMA Biologics Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks76th Percentile Overall ScoreADMA MarketRank™: ADMA Biologics scored higher than 76% of companies evaluated by MarketBeat, and ranked 249th out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.6 / 5Analyst RatingBuy Consensus RatingADMA Biologics has received a consensus rating of Buy. The company's average rating score is 3.25, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageADMA Biologics has only been the subject of 2 research reports in the past 90 days.Read more about ADMA Biologics' stock forecast and price target. Earnings and Valuation3.1 / 5Proj. Earnings Growth50.00% Earnings GrowthEarnings for ADMA Biologics are expected to grow by 50.00% in the coming year, from $0.52 to $0.78 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ADMA Biologics is 62.14, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 112.76.Price to Earnings Ratio vs. SectorThe P/E ratio of ADMA Biologics is 62.14, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 87.03.Price to Book Value per Share RatioADMA Biologics has a P/B Ratio of 29.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted5.46% of the outstanding shares of ADMA Biologics have been sold short.Short Interest Ratio / Days to CoverADMA Biologics has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in ADMA Biologics has recently decreased by 9.34%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldADMA Biologics does not currently pay a dividend.Dividend GrowthADMA Biologics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted5.46% of the outstanding shares of ADMA Biologics have been sold short.Short Interest Ratio / Days to CoverADMA Biologics has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in ADMA Biologics has recently decreased by 9.34%, indicating that investor sentiment is improving significantly. News and Social Media2.8 / 5News Sentiment1.09 News SentimentADMA Biologics has a news sentiment score of 1.09. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for ADMA Biologics this week, compared to 7 articles on an average week.Search InterestOnly 35 people have searched for ADMA on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.MarketBeat FollowsOnly 19 people have added ADMA Biologics to their MarketBeat watchlist in the last 30 days. This is a decrease of -10% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, ADMA Biologics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $317,250.00 in company stock.Percentage Held by InsidersOnly 3.70% of the stock of ADMA Biologics is held by insiders.Percentage Held by Institutions75.68% of the stock of ADMA Biologics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about ADMA Biologics' insider trading history. Receive ADMA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ADMA Biologics and its competitors with MarketBeat's FREE daily newsletter. Email Address ADMA Stock News HeadlinesADMA Biologics, Inc. (NASDAQ:ADMA) CFO Sells $317,250.00 in StockNovember 23, 2024 | insidertrades.comADMA Biologics (NASDAQ:ADMA) Shares Gap Down - Should You Sell?December 22 at 2:55 AM | americanbankingnews.comCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more than $9 trillion. That’s nearly 10 times more money than the market caps of Tesla… SpaceX… PayPal… Neuralink… and X… COMBINED.December 22, 2024 | Brownstone Research (Ad)ADMA Biologics Announces Partial Paydown of Senior Term Loan Credit FacilityDecember 20 at 7:00 AM | globenewswire.comApogee Therapeutics Trying To Close In On Key Technical MeasureDecember 17, 2024 | msn.comADMA Biologics, Inc. (NASDAQ:ADMA) Short Interest Down 9.3% in NovemberDecember 16, 2024 | americanbankingnews.comStocks With Rising Relative Strength: VaxcyteDecember 10, 2024 | msn.comMizuho Securities Remains a Buy on ADMA Biologics (ADMA)December 3, 2024 | markets.businessinsider.comSee More Headlines ADMA Stock Analysis - Frequently Asked Questions How have ADMA shares performed this year? ADMA Biologics' stock was trading at $4.52 on January 1st, 2024. Since then, ADMA stock has increased by 285.0% and is now trading at $17.40. View the best growth stocks for 2024 here. How were ADMA Biologics' earnings last quarter? ADMA Biologics, Inc. (NASDAQ:ADMA) released its quarterly earnings results on Thursday, November, 7th. The biotechnology company reported $0.15 EPS for the quarter, beating the consensus estimate of $0.13 by $0.02. The biotechnology company had revenue of $119.84 million for the quarter, compared to analysts' expectations of $107.25 million. ADMA Biologics had a net margin of 17.80% and a trailing twelve-month return on equity of 53.20%. Who are ADMA Biologics' major shareholders? ADMA Biologics' top institutional shareholders include State Street Corp (5.58%), Geode Capital Management LLC (2.31%), Two Sigma Advisers LP (1.91%) and Assenagon Asset Management S.A. (1.50%). Insiders that own company stock include Steve Elms, Adam S Grossman, Brian Lenz, Jerrold B Grossman, Kaitlin M Kestenberg-Messina, Young Kwon, Brad L Tade, Lawrence P Guiheen and Bryant Fong. View institutional ownership trends. How do I buy shares of ADMA Biologics? Shares of ADMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of ADMA Biologics own? Based on aggregate information from My MarketBeat watchlists, some other companies that ADMA Biologics investors own include Humana (HUM), Voyager Therapeutics (VYGR), American Water Works (AWK), Waste Connections (WCN), The RMR Group (RMR), AUO (AUOTY) and DiamondRock Hospitality (DRH). Company Calendar Last Earnings11/07/2024Today12/22/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ADMA CUSIPN/A CIK1368514 Webwww.admabiologics.com Phone(201) 478-5552Fax201-478-5553Employees530Year FoundedN/APrice Target and Rating Average Stock Price Target$21.25 High Stock Price Target$26.00 Low Stock Price Target$14.00 Potential Upside/Downside+22.1%Consensus RatingBuy Rating Score (0-4)3.25 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)$0.28 Trailing P/E Ratio62.14 Forward P/E Ratio33.46 P/E GrowthN/ANet Income$-28,240,000.00 Net Margins17.80% Pretax Margin19.16% Return on Equity53.20% Return on Assets26.07% Debt Debt-to-Equity Ratio0.48 Current Ratio7.09 Quick Ratio3.26 Sales & Book Value Annual Sales$382.81 million Price / Sales10.74 Cash Flow$0.05 per share Price / Cash Flow386.28 Book Value$0.60 per share Price / Book29.00Miscellaneous Outstanding Shares236,390,000Free Float227,644,000Market Cap$4.11 billion OptionableOptionable Beta0.70 Social Links 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report This page (NASDAQ:ADMA) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredWhy Buffett, Griffin and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ADMA Biologics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ADMA Biologics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.